Giuliani Stefano, Paraboschi Irene, McNair Angus, Smith Myles, Rankin Kenneth S, Elson Daniel S, Paleri Vinidh, Leff Daniel, Stasiuk Graeme, Anderson John
Wellcome/EPSRC Centre for Interventional and Surgical Sciences, University College London, London W1W 7TY, UK.
Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.
Cancers (Basel). 2024 Mar 4;16(5):1045. doi: 10.3390/cancers16051045.
This study aims to review the status of the clinical use of monoclonal antibodies (mAbs) that have completed or are in ongoing clinical trials for targeted fluorescence-guided surgery (T-FGS) for the intraoperative identification of the tumor margins of extra-hematological solid tumors. For each of them, the targeted antigen, the mAb generic/commercial name and format, and clinical indications are presented, together with utility, doses, and the timing of administration. Based on the current scientific evidence in humans, the top three mAbs that could be prepared in a GMP-compliant bank ready to be delivered for surgical purposes are proposed to speed up the translation to the operating room and produce a few readily available "off-the-shelf" injectable fluorescent probes for safer and more effective solid tumor resection.
本研究旨在回顾已完成或正在进行针对血液外实体瘤肿瘤边缘术中识别的靶向荧光引导手术（T-FGS）的单克隆抗体（mAb）的临床应用状况。对于每种单克隆抗体，均介绍了其靶向抗原、通用名/商品名及剂型、临床适应症，以及效用、剂量和给药时间。基于目前人类的科学证据，提出了三种可在符合药品生产质量管理规范（GMP）的库中制备、随时可供手术使用的单克隆抗体，以加快向手术室的转化，并生产一些现成的“即用型”可注射荧光探针，用于更安全、更有效的实体瘤切除。
